ECaBox Eyes in a Care Box Regenerating human retina from resuscitated cada...
ECaBox Eyes in a Care Box Regenerating human retina from resuscitated cadaveric eyes
In the last decade, basic and translational research dramatically expanded the development of new drug and regenerative therapies. Nevertheless, numerous potential therapies end up in the valley of death due to high attrition rate...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto ECaBox
Duración del proyecto: 55 meses
Fecha Inicio: 2021-01-20
Fecha Fin: 2025-08-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
In the last decade, basic and translational research dramatically expanded the development of new drug and regenerative therapies. Nevertheless, numerous potential therapies end up in the valley of death due to high attrition rates of preclinical development. More cost-effective preclinical research is needed to support radically new therapeutic interventions (e.g. regenerative medicine). Yet, preclinical research still lacks adequate models of human organs and even though human organoids approaches are a major step forward in mimicking physiological conditions, they fail to reflect the overall tissue physiology and complexity. To address this demand, we aim to develop a revolutionary platform, the ECaBox (Eyes in a Care Box) to resuscitate the human cadaveric eye while ensuring eye function and structure ex vivo for an unmatched time-period. This new technology will challenge current paradigms of testing the efficacy and safety of regenerative therapies ex vivo. We will therefore, explore the potential of this forefront technology by testing a regenerative therapy approach for retina degeneration. Currently, human eyes can be kept at 4ºC for 2 days before going massive and irreversible cell and tissue damage. Human dissected retinae from cadaveric eyes can be preserved for maximum 1 week and non-vascularised human eye organoids fail to recapitulate the vascular and tissue systems. Hence, ECaBox will be a disruptive technology with a tremendous impact allowing to: 1) resuscitate human eyes to test human eye therapies ex vivo, 2) bypass major ethical restrictions of human experimentation, 3) serve as a proof of concept to develop therapies also in other organs preserved ex vivo and 4) transform the existing organ transplantation field. This is a highly interdisciplinary project that integrates expertise in biology, biotechnology, modelling, engineering and physics.